Zetonna is a drug owned by Covis Pharma Gmbh. It is protected by 9 US drug patents filed in 2013. Out of these, 1 drug patents are active and 8 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 01, 2028. Details of Zetonna's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8371292 | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(2 years from now) | Active |
| US6264923 | Medicinal aerosol formulation of ciclesonide and related compounds |
May, 2018
(7 years ago) |
Expired
|
| US6120752 | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
May, 2018
(7 years ago) |
Expired
|
| US5482934 | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(8 years ago) |
Expired
|
| US6006745 | Device for delivering an aerosol |
Dec, 2016
(8 years ago) |
Expired
|
| US5775321 | Seal configuration for aerosol canister |
Jul, 2015
(10 years ago) |
Expired
|
| US5683677 | Medicinal aerosol formulations |
Nov, 2014
(10 years ago) |
Expired
|
| US5605674 | Medicinal aerosol formulations |
Feb, 2014
(11 years ago) |
Expired
|
| US6036942 | Seal configuration for aerosol canister |
Apr, 2013
(12 years ago) |
Expired
|
FDA has granted several exclusivities to Zetonna. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Zetonna, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Zetonna.
Exclusivity Information
Zetonna holds 1 exclusivities. All of its exclusivities have expired in 2015. Details of Zetonna's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 20, 2015 |
Several oppositions have been filed on Zetonna's European patents.
EP oppositions
can significantly impact the timeline for the generic launch of drugs. If an opposition results in the
revocation or
amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an
earlier entry
of generic versions into the market. To help you estimate the potential early arrival of Zetonna's generic, the next section provides detailed information on
ongoing and past
EP oppositions related to Zetonna patents.
Zetonna's Oppositions Filed in EPO
Zetonna has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 25, 2014, by Generics [Uk] Ltd (Trading As Mylan). This opposition was filed on patent number EP04766791A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP04766791A | Sep, 2014 | Generics [UK] Ltd (trading as Mylan) | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but
Zetonna is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Zetonna's family patents as well as insights into
ongoing legal events
on those patents.
Zetonna's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zetonna's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 01, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zetonna Generics:
There are no approved generic versions for Zetonna as of now.
Alternative Brands for Zetonna
Zetonna which is used for treating inflammatory conditions, seasonal and perennial allergic rhinitis in adults and adolescents, and respiratory diseases in children., has several other brand drugs in the same treatment category and using the same active ingredient (Ciclesonide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Covis |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Ciclesonide. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Covis |
|
About Zetonna
Zetonna is a drug owned by Covis Pharma Gmbh. It is used for treating inflammatory conditions, seasonal and perennial allergic rhinitis in adults and adolescents, and respiratory diseases in children. Zetonna uses Ciclesonide as an active ingredient. Zetonna was launched by Covis in 2012.
Approval Date:
Zetonna was approved by FDA for market use on 20 January, 2012.
Active Ingredient:
Zetonna uses Ciclesonide as the active ingredient. Check out other Drugs and Companies using Ciclesonide ingredient
Treatment:
Zetonna is used for treating inflammatory conditions, seasonal and perennial allergic rhinitis in adults and adolescents, and respiratory diseases in children.
Dosage:
Zetonna is available in aerosol, metered form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.037MG/INH | AEROSOL, METERED | Discontinued | NASAL |